Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Intrarenal dopamine inhibits progression of diabetic nephropathy.

Diabetes | 2012

The kidney has a local intrarenal dopaminergic system, and in the kidney, dopamine modulates renal hemodynamics, inhibits salt and fluid reabsorption, antagonizes the renin-angiotensin system, and inhibits oxidative stress. The current study examined the effects of alterations in the intrarenal dopaminergic system on kidney structure and function in models of type 1 diabetes. We studied catechol-O-methyl-transferase (COMT)(-/-) mice, which have increased renal dopamine production due to decreased dopamine metabolism, and renal transplantation was used to determine whether the effects seen with COMT deficiency were kidney-specific. To determine the effects of selective inhibition of intrarenal dopamine production, we used mice with proximal tubule deletion of aromatic amino acid decarboxylase (ptAADC(-/-)). Compared with wild-type diabetic mice, COMT(-/-) mice had decreased hyperfiltration, decreased macula densa cyclooxygenase-2 expression, decreased albuminuria, decreased glomerulopathy, and inhibition of expression of markers of inflammation, oxidative stress, and fibrosis. These differences were also seen in diabetic mice with a transplanted kidney from COMT(-/-) mice. In contrast, diabetic ptAADC(-/-) mice had increased nephropathy. Our study demonstrates an important role of the intrarenal dopaminergic system to modulate the development and progression of diabetic kidney injury and indicate that the decreased renal dopamine production may have important consequences in the underlying pathogenesis of diabetic nephropathy.

Pubmed ID: 22688335 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: P60 DK020593
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK079341
  • Agency: NCI NIH HHS, United States
    Id: R01 CA122620
  • Agency: NIDDK NIH HHS, United States
    Id: P01 DK038226
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK095785
  • Agency: NIDDK NIH HHS, United States
    Id: DK-20593
  • Agency: NCI NIH HHS, United States
    Id: CA-122620
  • Agency: NIDDK NIH HHS, United States
    Id: DK-62794
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK020593
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK051265
  • Agency: NIDDK NIH HHS, United States
    Id: DK-59637
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK062794
  • Agency: NIDDK NIH HHS, United States
    Id: DK-79341
  • Agency: NIDDK NIH HHS, United States
    Id: DK-38226
  • Agency: NIDDK NIH HHS, United States
    Id: U24 DK059637
  • Agency: NIDDK NIH HHS, United States
    Id: DK-51265

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


National Mouse Metabolic Phenotyping Centers (tool)

RRID:SCR_008997

The mission is to advance medical and biological research by providing the scientific community with standardized, high quality metabolic and physiologic phenotyping services for mouse models of diabetes, diabetic complications, obesity and related disorders.

View all literature mentions